Sorted By:

Relevance


BIO/PhRMA Principles on Responsible Sharing of Truthful and Non-Misleading Information about Medicines with Health Care Professionals and Payers

PhRMA  |  Codes & Guidelines

The Principles pertain primarily to data and information outside of FDA-approved labeling, and are intended to establish responsible, science-based parameters for accurate and trusted information sharing.
https://www.phrma.org/codes-and-guidelines/bio/phrma-principles-on-responsible-sharing-of-truthful-and-non-misleading-information-about-medicines-with-health-care-professionals-and-payers

The Time Has Arrived for Patent Reform

PhRMA  |  Blog Post

The bill (S23) would also encourage a positive environment for developing ideas that become life-changing innovations.
http://catalyst.phrma.org/the-time-has-arrived-for-patent-reform

Chip Meyers, Jr.

PhRMA  |  Biography

They have three daughters and now make their home in Oakton, VA.
https://www.phrma.org/biography/chip-meyers-jr

Follow the Dollar: Flow of Payment for a $100 Blood Pressure Medicine

PhRMA  |  Graphic

Because Janet’s health plan receives a 25% rebate off of the list price of her medicine, her copayment of $40.00 is slightly more than the $38.00 net price paid by her health plan.
https://www.phrma.org

Disease modifying therapies for the management of multiple sclerosis save money and improve patient outcomes

PhRMA  |  Blog Post

The study’s results highlight the positive impact that these innovative therapies may have, both for patients with MS and for the health care system as a whole.
http://catalyst.phrma.org/disease-modifying-therapies-for-the-management-of-multiple-sclerosis-save-money-and-improve-patient-outcomes

Need for New Treatments for Alzheimer's

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/need-for-new-treatments-for-alzheimer-s

Opportunities to build upon enhanced competition for medicines in the marketplace

PhRMA  |  Blog Post

Fostering robust innovation will continue to enhance the competitive marketplace for biopharmaceuticals.
http://catalyst.phrma.org/opportunities-to-build-upon-enhanced-competition-for-medicines-in-the-marketplace

The Five Essential Truths about Prescription Drug Spending

PhRMA  |  Blog Post

And new hepatitis C therapies have cure rates above 90 percent and dramatically decrease the burden of the disease on the U.S. health care system and the economy.
http://catalyst.phrma.org/the-five-essential-truths-about-prescription-drug-spending

Medicare Monday: A guide to MedPAC’s Part B vote this week

PhRMA  |  Blog Post

These proposed changes to Medicare Part B could have a detrimental impact on access for patients who rely on Part B therapies.
http://catalyst.phrma.org/medicare-monday-a-guide-to-medpacs-part-b-vote-this-week

How patients with dyslipidemia save with Medicare Part D

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/how-patients-with-dyslipidemia-save-with-medicare-part-d

Medicines in Development for Arthritis, 2014

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/medicines-in-development-for-arthritis-2014

High Cholesterol Patient Profile - George

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/high-cholesterol-patient-profile-george

Five Facts About the Value of Innovative Cancer Medicines

PhRMA  |  Blog Post

“Benefit Designs for High Cost Medical Conditions.
http://catalyst.phrma.org/five-facts-about-the-value-of-innovative-cancer-medicines

Driving Innovation and Economic Growth for the 21st Century

PhRMA  |  Report

For years, states have taken the lead in advancing strategic, innovation-led, industry cluster development efforts.
https://www.phrma.org

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

PhRMA  |  Blog Post

Improve capability for measurement through initiatives that make it easier for stakeholders to track outcomes across the health system, prioritizing measurement of factors that matter most to patients.
http://catalyst.phrma.org/icymi-survey-highlights-key-barriers-limiting-number-and-scale-of-new-approaches-to-paying-for-medicines

340B Spotlight: Myth vs. Fact

PhRMA  |  Graphic

Unfortunately, over the years a lot of myths have been perpetuated about how the program works and who it benefits.
https://www.phrma.org/graphic/340b-spotlight-myth-vs-fact

Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B, 2006-2015

PhRMA  |  Report

This broader perspective more accurately captures marketplace dynamics, providing a more appropriate picture of drug cost trends.
https://www.phrma.org/report/trends-in-weighted-average-sales-prices-for-prescription-drugs-in-medicare-part-b-2006-2015

How innovative medicines are benefiting countries across the globe

PhRMA  |  Blog Post

The development of new medicines is critical for managing future health care spending.
http://catalyst.phrma.org/how-innovative-medicines-are-benefiting-countries-across-the-globe

A New Negotiation: Moving Payment for Medicines from Volume to Value

PhRMA  |  Video

At this event on February 23, 2017, America's biopharmaceutical companies discussed ways the private prescription medicine marketplace can evolve to produce and reward better value for patients.
https://www.phrma.org/video/a-new-negotiation-moving-payment-for-medicines-from-volume-to-value

Medicare Monday: Billing code basics for biologics in Part B

PhRMA  |  Blog Post

Proposals like blended coding could have even more harmful consequences for patients down the road and could hurt the competitive market for Part B medicines.
http://catalyst.phrma.org/medicare-monday-billing-code-basics-biologics-part-b

Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients

PhRMA  |  Blog Post

Learn more about why drug importation is bad for patients here.
http://catalyst.phrma.org/discovery-of-counterfeit-hepatitis-c-drug-is-another-example-of-why-importation-is-bad-for-patients

Medicare Monday: What is IPAB, and why is it bad for patients?

PhRMA  |  Blog Post

  Additionally, several members of Congress have recently called for the repeal of IPAB, including Senator Wyden, Senator Cornyn and .house.gov/news/documentsingle.aspx?
http://catalyst.phrma.org/medicare-monday-what-is-ipab-and-why-is-it-bad-for-patients

Patient Profile: How Medicare Part D Extra Help Works - Katie

PhRMA  |  Graphic

Learn more about this patient story.
https://www.phrma.org/graphic/patient-profile-how-medicare-part-d-extra-help-works-katie

Medicines in Development for COPD 2012 Report

PhRMA  |  Report

“The promising new therapies highlighted in this report illustrate how emerging scientific approaches, to treating respiratory diseases such as COPD, offer great hope to improve and save the lives of future patients.”
https://www.phrma.org/report/medicines-in-development-for-copd-report

Value of Cancer Medicines

PhRMA  |  Graphic

...
https://www.phrma.org/graphic/value-of-cancer-medicines

You have reviewed the first 200 results out of 2564. Each page contains 25 results. You're on page 8.

prev 7 8 9 10 11 12 next